Skip to main content
. 2017 Mar 10;123(12):2294–2302. doi: 10.1002/cncr.30661

Table 1.

Q‐TWiST: Base‐Case Analysis and Sensitivity Analysis

Q‐TWiST, mo (95% CI) Difference,
Definition of TOX Placebo Regorafenib mo (95% CI) P
Base‐case analysis: every classic adverse event ≥ grade 3 5.68 (4.92‐6.45) 7.97 (6.96‐8.97) 2.28 (1.02‐3.55) <.001
1. Every toxicity regarded as at least slightly unacceptable by at least 20% of interviewed patients 5.38 (4.65‐6.11) 6.52 (5.70‐7.33) 1.14 (0.04‐2.24) .043
2. Every toxicity regarded as at least slightly unacceptable by at least 33% of interviewed patients 5.52 (4.80‐6.23) 6.81 (5.95‐7.69) 1.30 (0.19‐2.41) .022
3. Every toxicity regarded as at least slightly unacceptable by at least 50% of interviewed patients 5.60 (4.85‐6.35) 7.27 (6.33‐8.21) 1.67 (0.46‐2.88) .007
4. Every toxicity regarded as unacceptable or totally unacceptable by at least 20% of interviewed patients 5.58 (4.83‐6.34) 7.09 (6.18‐8.0) 1.51 (0.33‐2.70) .012
5. Every toxicity regarded as unacceptable or totally unacceptable by at least 33% of interviewed patients 5.71 (4.95‐6.47) 7.49 (6.59‐8.40) 1.79 (0.58‐2.99) .004
6. Every toxicity regarded as unacceptable or totally unacceptable by at least 50% of interviewed patients 5.74 (4.99‐6.49) 7.85 (6.86‐8.84) 2.11 (0.87‐3.35) .001

Abbreviations: CI, confidence interval; Q‐TWiST, quality‐adjusted time without symptoms of progression or toxicity; TOX, time with a grade 3 or 4 adverse event.